公开(公告)号：US20150265613A1

公开(公告)日：2015-09-24

申请号：US14671030

申请日：2015-03-27

Applicant: AbbVie Inc.

Inventor： R. Scott Bitner ,  Kaitlin E. Browman ,  Michael E. Brune ,  Steven Fung ,  Peer B. Jacobson ,  Lynne E. Rueter ,  Marina I. Strakhova ,  Jiahong Wang ,  Jeffrey J. Rohde ,  Qi Shuai ,  James T. Link ,  Jyoti R. Patel ,  Jurgen Dinges ,  Bryan K. Sorensen ,  Hong Yong ,  Vince S. Yeh ,  Ravi Kurukulasuriya

IPC: A61K31/498 ,  A61K31/165 ,  A61K31/4409 ,  A61K31/415 ,  A61K31/44 ,  A61K31/451 ,  A61K31/4015 ,  A61K31/196 ,  A61K31/381

CPC classification number: A61K31/498 ,  A61K31/165 ,  A61K31/195 ,  A61K31/196 ,  A61K31/381 ,  A61K31/4015 ,  A61K31/415 ,  A61K31/44 ,  A61K31/4409 ,  A61K31/45 ,  A61K31/451 ,  A61K31/5377 ,  C07C233/11 ,  C07C233/52 ,  C07C233/58 ,  C07C233/63 ,  C07C237/24 ,  C07C311/46 ,  C07C2601/02 ,  C07C2601/04 ,  C07C2601/08 ,  C07C2601/14 ,  C07C2603/74 ,  C07D207/277 ,  C07D211/78 ,  C07D213/56 ,  C07D231/12 ,  C07D261/08 ,  C07D333/24

Abstract: The present invention relates to inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme and their use in treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, central nervous system disorders, and diseases and conditions that are related to excessive glucocorticoids.

公开(公告)号：US09290444B2

公开(公告)日：2016-03-22

申请号：US14226615

申请日：2014-03-26

Applicant: ABBVIE INC.

Inventor： R. Scott Bitner ,  Kaitlin E. Browman ,  Michael E. Brune ,  Steven Fung ,  Peer B. Jacobson ,  Lynne E. Rueter ,  Marina I. Strakhova ,  Jiahong Wang ,  Jyoti R. Patel ,  Qi Shuai ,  James T. Link ,  Jeffrey J. Rohde ,  Jurgen Dinges ,  Bryan K. Sorensen ,  Martin Winn ,  Hong Yong ,  Vince S. Yeh

IPC: C07C235/14 ,  A61K31/165 ,  A61K31/19 ,  A61K31/4439 ,  C07C235/22 ,  C07C237/24 ,  C07C271/28 ,  C07C311/46 ,  C07D207/48 ,  C07D257/04 ,  C07D261/08 ,  C07D295/088 ,  C07D401/04

CPC classification number: C07C235/14 ,  A61K31/165 ,  A61K31/19 ,  A61K31/4439 ,  C07C235/22 ,  C07C237/24 ,  C07C271/28 ,  C07C311/46 ,  C07C2601/14 ,  C07C2601/18 ,  C07C2603/74 ,  C07D207/48 ,  C07D257/04 ,  C07D261/08 ,  C07D295/088 ,  C07D401/04

Abstract: The present invention relates to inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme and their use in treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, central nervous system disorders, and diseases and conditions that are related to excessive glucocorticoids.